The United Kingdom’s medicines regulator has authorized the initiation of human clinical trials for a novel Ebola vaccine developed by researchers at the University of Oxford. The vaccine development began eight weeks prior, following the declaration of a public health emergency on 17 May. This marks the first of four vaccines currently under development to advance to clinical testing in humans.
The outbreak involves the Bundibugyo species of Ebola and has resulted in 625 deaths among 1,792 laboratory confirmed cases, primarily affecting the Democratic Republic of the Congo. The region’s ongoing conflict and mobile populations have complicated containment efforts, underscoring the urgency of vaccine development. The Bundibugyo strain represents a distinct species requiring a separate vaccine approach, as approved treatments and vaccines do not currently exist for this variant.
The Oxford team leveraged technology that gained prominence during the COVID-19 pandemic, utilizing a genetically modified chimpanzee cold virus as a delivery mechanism. The vaccine contains a snippet of genetic code from the Bundibugyo species, which triggers the body’s immune system to recognize and respond to the threat. Initial animal testing and manufacturing to clinical standards have been completed, with approximately 620,000 doses stockpiled by the Serum Institute of India.
The clinical trial will involve 50 healthy adults aged 18-55 in the UK, with initial doses anticipated within weeks. Participants will be monitored over one year, allowing researchers to assess immune response and any adverse effects. Researchers are simultaneously preparing for trials in Uganda and other African locations. While the accelerated development timeline compresses typical vaccine research into parallel processes rather than sequential phases, researchers assert that all standard safety and efficacy testing remains intact.
Three additional vaccine candidates are under development using alternative technologies, including an mRNA-based approach from Moderna and methods previously validated for other Ebola species. The Oxford vaccine carries a theoretical risk profile comparable to its COVID-19 predecessor, though health officials emphasize that the threat posed by Bundibugyo Ebola, which kills approximately one-third of infected individuals, substantially outweighs documented vaccine risks.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI